33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Strategies to improve the sensitivity and ranking ability of neoantigen prediction methods: Report on the results of the Tumor nEoantigen SeLection Alliance (TESLA)
    Meeting Abstract

    Wells, D. K.; Dang, K.; Hubbard-Lucey, V. M.; Sheehan, K. C.; Lamb, A.; Ward, J. P.; Sidney, J.; Blazquez, A. B.; Rech, A. J.; Zaretsky, J.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • The protein phosphatase 4 complex is a tumor suppressor in prostate cancer
    Meeting Abstract

    Watson, P. A.; Lawrence, K. E.; Nadkarni, T. V.; Ishmael, T. F.; Lee, E.; Agudelo Rivera, A. C.; Love, J. R.; Wongvipat, J.; Cai, L.; Nazir, A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Immuno-transcriptomic profiling identifies actionable genomic alterations in pediatric solid malignancies
    Meeting Abstract

    Wei, J. S.; Brohl, A. S.; Sindiri, S.; Milewski, D.; Song, Y. K.; Nagaraj, S.; Gangalapudi, V.; Wen, X.; Ladanyi, M.; Khan, J.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • RNAi rat models for drug discovery
    Meeting Abstract

    Wang, C. L.; Yang, Y. T.; Vasileva, A.; Maurice, A.; Dow, L.; Zuber, J.; Lowe, S.; Premsrirut, P. K.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Harmonization standards from the Variant Interpretation for Cancer Consortium
    Meeting Abstract

    Wagner, A. H.; Hart, R. K.; Babb, L.; Freimuth, R. R.; Coffman, A.; Liang, Y.; Pitel, B.; Roy, A.; Brush, M.; Lee, J.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Sweeney, C. J.; Gillessen, S.; Rathkopf, D.; Matsubara, N.; Drake, C.; Fizazi, K.; Piulats, J. M.; Wysocki, P. J.; Buchschacher, G. L. Jr; Doss, J.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A computational model for the PI3K/Akt/mTOR pathway predicts PTEN as a negative feedback loop
    Meeting Abstract

    Vanaja, K.; Mukherjee, R.; Rosen, N.; Levchenko, A.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Chromatin accessibility landscape and transcriptome of castration resistant prostate cancers reveals novel subtypes and diverse master regulators
    Meeting Abstract

    Tang, F.; Wong, C. K.; Cohen, S.; Lee, C.; Liu, M.; Bareja, R.; Eng, K.; Beg, S.; Puca, L.; Sternberg, C.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • OncoKB, a precision oncology knowledgebase
    Meeting Abstract

    Suehnholz, S.; Zhang, H.; Nissan, M.; Kundra, R.; Su, J.; LaFave, L.; Gala, K.; Vanderbilt, C.; Arcila, M.; Ladanyi, M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save